School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Alan Gordon MD

  • Department of Gynecology & Obstetrics
    Professor
  • (404) 778-3401
  • alan.n.gordon@emory.edu
Head shot of Alan Gordon

Overview

Alan N. Gordon, MD, has been board certified in both obstetrics and gynecology since 1985. He specializes in gynecologic oncology and is the Division Director of Gynecologic Oncology at Emory.

Dr. Gordon is a member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He is also a member of the American College of Obstetricians and Gynecologists, the Society of Gynecologic Oncologists, the Felix Rutlege Society, the American Society of Clinical Oncology, the International Society of Gynecologic Oncology, the European Society of Medical Oncology, the American College of Surgeons, and the Johns Hopkins Medical and Surgical Society.

Academic Appointment

Education

Degrees

  • MD from The Johns Hopkins University School of Medicine
  • BA from The Johns Hopkins University

Research

Focus

  • My major interest is in the area clinical drug development. The majority of my work has been in phase II and III trials to evaluate efficacy and safety of new drugs and combinations in gynecologic cancers. I have also bee involved in phase I safety trials of chemotherapeutic regimens.

Publications

  • Incidence and predictors of toxicity in the management of vulvar squamous cell carcinoma treated with radiation therapy.
    Gynecol Oncol Rep Volume: 44 Page(s): 101086
    12/01/2022 Authors: McCall NS; Eng TY; Shelton JW; Hanasoge S; Patel PR; Patel AB; McCook-Veal AA; Switchenko JM; Cole TE; Khanna N
  • Thirty-day Postoperative Adverse Events in Minimally Invasive versus Open Abdominal Radical Hysterectomy for Early-stage Cervical Cancer.
    J Minim Invasive Gynecol Volume: 29 Page(s): 840 - 847
    07/01/2022 Authors: Kohut AY; Kuhn T; Conrad LB; Chua KJ; Abuelafiya M; Gordon AN; Flowers L; Orfanelli T; Blank S; Khanna N
  • Effect of Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain: A Randomized Clinical Trial.
    JAMA Psychiatry Volume: 79 Page(s): 13 - 23
    01/01/2022 Authors: Ashar YK; Gordon A; Schubiner H; Uipi C; Knight K; Anderson Z; Carlisle J; Polisky L; Geuter S; Flood TF
  • Clinical Outcomes and Assessment of Racial Disparities for Vulvar Squamous Cell Carcinoma Treated With Radiotherapy.
    Int J Radiat Oncol Biol Phys Volume: 111 Page(s): e637 - e638
    11/01/2021 Authors: Remick JS; McCall NS; Khanna N; Shelton JW; Hanasoge S; Patel PR; Patel AB; Cole T; McCook A; Gordon AN
  • Severe Toxicity and Provider-Reported Subjective Symptoms in Patients With Vulvar Cancer Receiving Curative-Intent Radiotherapy.
    Int J Radiat Oncol Biol Phys Volume: 111 Page(s): e636
    11/01/2021 Authors: McCall NS; Eng TY; Shelton JW; Hanasoge S; Patel PR; Patel AB; McCook A; Switchenko J; Cole T; Khanna N
  • Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy.
    Int J Gynecol Pathol Volume: 40 Page(s): 501 - 509
    09/01/2021 Authors: Hanley KZ; Horowitz IR; Gordon A; Meisel J; Khanna N
  • Citation classics in gynecologic oncology: A bibliometric analysis
    GYNECOLOGIC ONCOLOGY Volume: 159 Page(s): 305 - 305
    10/01/2020 Authors: Kohut A; Booher M; Naumova AD; Kuhn T; Southern GK; Flowers L; Conrad LB; Gordon AN; Khanna N
  • Evaluating risk factors for surgical site infection following minimally invasive surgery for endometrial cancer
    GYNECOLOGIC ONCOLOGY Volume: 159 Page(s): 304 - 305
    10/01/2020 Authors: Kohut A; Kuhn T; Booher M; Naumova AD; Southern GK; Flowers L; Conrad LB; Gordon AN; Rodriguez L; Khanna N
  • Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    Lancet Oncol Volume: 20 Page(s): 862 - 876
    06/01/2019 Authors: Vergote I; Scambia G; O'Malley DM; Van Calster B; Park S-Y; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM
  • What Should a Gynecologist Know about Li-Fraumeni Syndrome? Lessons from a Patient Undergoing Hysterectomy for Benign Indications.
    Gynecol Obstet Invest Volume: 83 Page(s): 410 - 414
    01/01/2018 Authors: Advolodkina P; Lachiewicz MP; Oprea-Ilies G; Majmudar B; Gordon AN
  • Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer.
    Int J Gynecol Cancer Volume: 27 Page(s): 1333 - 1342
    09/01/2017 Authors: Alexander VM; Gordon AN; Howard DH; Khanna N
  • Long-term remission of clear cell carcinoma of the cervix after chemoradiation with 109 cycles of paclitaxel: a case report and literature review.
    Eur J Gynaecol Oncol Volume: 38 Page(s): 456 - 458
    01/01/2017 Authors: Lachiewicz MP; Khanna N; Gordon AN; Horowitz IR
  • NEOVAGINAL CONDYLOMATOSIS AND CARCINOMA FOLLOWING MCINDOEVAGINOPLASTY.
    Volume: 106 Page(s): E129 - E129
    09/01/2016 Authors: Schirmer DA; Gordon AN; Roberts CP
  • Ovarian carcinoma initially presenting as breast cancer two years prior to diagnosis: A case report and review of literature.
    Gynecol Oncol Rep Volume: 15 Page(s): 29 - 30
    01/01/2016 Authors: Rauh LA; Lachiewicz MP; Gordon AN
  • A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Gynecol Oncol Volume: 135 Page(s): 25 - 33
    10/01/2014 Authors: Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S
  • Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gynecol Oncol Volume: 123 Page(s): 479 - 485
    12/01/2011 Authors: Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL
  • Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
    Clin Cancer Res Volume: 16 Page(s): 5320 - 5328
    11/01/2010 Authors: Chambers SK; Clouser MC; Baker AF; Roe DJ; Cui H; Brewer MA; Hatch KD; Gordon MS; Janicek MF; Isaacs JD
  • Re: Radical abdominal trachelectomy for (microscopic) stage IB1 cervical cancer at 15-week gestation.
    Gynecol Oncol Volume: 118 Page(s): 97
    07/01/2010 Authors: Gordon AN; Schimp VL
  • Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.
    Volume: 28
    06/20/2010 Authors: Teneriello MG; Gordon AN; Lim P; Janicek M
  • Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer
    Volume: 28
    05/20/2010 Authors: Wenham RM; Leach JW; Scudder SA; Amin BR; Pippitt CH; Gordon AN; Nanayakkara N; Hurh E; Stepan DE; Schilder RJ
  • Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
    J Oncol Pract Volume: 6 Page(s): 133 - 140
    05/01/2010 Authors: Burris HA; Belani CP; Kaufman PA; Gordon AN; Schwartzberg LS; Paroly WS; Shahin S; Dreiling L; Saven A
  • The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
    J Immunother Volume: 32 Page(s): 54 - 65
    01/01/2009 Authors: Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM
  • Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
    J Clin Oncol Volume: 26 Page(s): 2674 - 2682
    06/01/2008 Authors: Lhomm C; Joly F; Walker JL; Lissoni AA; Nicoletto MO; Manikhas GM; Baekelandt MMO; Gordon AN; Fracasso PM; Mietlowski WL
  • Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Interim analysis of induction chemotherapy
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Gordon AN; Teneriello MG; Spirtos N; Janicek MF; Goss T; Wang Y; Orlando M; Obasaju CK; Gill JF; Tai DF
  • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
    J Clin Oncol Volume: 25 Page(s): 2811 - 2818
    07/01/2007 Authors: Mutch DG; Orlando M; Goss T; Teneriello MG; Gordon AN; McMeekin SD; Wang Y; Scribner DR; Marciniack M; Naumann RW
  • Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
    Oncologist Volume: 12 Page(s): 72 - 78
    01/01/2007 Authors: Coleman RL; Gordon A; Barter J; Sun S; Rackoff W; Herzog TJ
  • A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
    Gynecol Oncol Volume: 101 Page(s): 55 - 61
    04/01/2006 Authors: Seiden MV; Gordon AN; Bodurka DC; Matulonis UA; Penson RT; Reed E; Alberts DS; Weems G; Cullen M; McGuire WP
  • Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct)
    EJC SUPPLEMENTS Volume: 3 Page(s): 262 - 262
    10/01/2005 Authors: Mutch D; Orlando M; Teneriello T; Gordon A; McMeekin S; Goss T; Scribner D; Naumann R; Secord AA; Wang Y
  • Final analysis of a randomized dosing study of oregovornab in patients with advanced ovarian cancer.
    Volume: 23 Page(s): 463S - 463S
    06/01/2005 Authors: Method MW; Gordon AN; Finkler N; Cieszynski J; Nicodemus C
  • Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
    Int J Gynecol Cancer Volume: 15 Page(s): 785 - 792
    01/01/2005 Authors: Gordon AN; Finkler N; Edwards RP; Garcia AA; Crozier M; Irwin DH; Barrett E
  • Role of pegylated liposomal doxorubicin in ovarian cancer.
    Gynecol Oncol Volume: 96 Page(s): 10 - 18
    01/01/2005 Authors: Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
  • Validation of referral guidelines for women with pelvic masses.
    Obstet Gynecol Volume: 105 Page(s): 35 - 41
    01/01/2005 Authors: Im SS; Gordon AN; Buttin BM; Leath CA; Gostout BS; Shah C; Hatch KD; Wang J; Berman ML
  • Liposomal anthracycline treatment for ovarian cancer.
    Semin Oncol Volume: 31 Page(s): 91 - 105
    12/01/2004 Authors: Markman M; Gordon AN; McGuire WP; Muggia FM
  • Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    J Natl Cancer Inst Volume: 96 Page(s): 1682 - 1691
    11/17/2004 Authors: Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB
  • Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
    Gynecol Oncol Volume: 95 Page(s): 1 - 8
    10/01/2004 Authors: Gordon AN; Tonda M; Sun S; Rackoff W; Doxil Study 30-49 Investigators
  • Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.
    J Clin Oncol Volume: 22 Page(s): 3507 - 3516
    09/01/2004 Authors: Berek JS; Taylor PT; Gordon A; Cunningham MJ; Finkler N; Orr J; Rivkin S; Schultes BC; Whiteside TL; Nicodemus CF
  • Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med Volume: 10 Page(s): 942 - 949
    09/01/2004 Authors: Curiel TJ; Coukos G; Zou L; Alvarez X; Cheng P; Mottram P; Evdemon-Hogan M; Conejo-Garcia JR; Zhang L; Burow M
  • Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol Volume: 94 Page(s): 533 - 539
    08/01/2004 Authors: Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
  • CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
    Gynecol Oncol Volume: 94 Page(s): 340 - 351
    08/01/2004 Authors: Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
  • Chemotherapeutic management of advanced ovarian cancer.
    Semin Oncol Nurs Volume: 19 Page(s): 3 - 18
    08/01/2003 Authors: Gordon AN; Butler J
  • A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.
    Gynecol Oncol Volume: 90 Page(s): 64 - 69
    07/01/2003 Authors: McMeekin DS; Gordon A; Fowler J; Melemed A; Buller R; Burke T; Bloss J; Sabbatini P
  • Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
    Nat Med Volume: 9 Page(s): 562 - 567
    05/01/2003 Authors: Curiel TJ; Wei S; Dong H; Alvarez X; Cheng P; Mottram P; Krzysiek R; Knutson KL; Daniel B; Zimmermann MC
  • A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma.
    Cancer Immunol Immunother Volume: 52 Page(s): 243 - 248
    04/01/2003 Authors: Chan SY; Gordon AN; Coleman RE; Hall JB; Berger MS; Sherman ML; Eten CB; Finkler NJ
  • Use of OvaRex(r) MAb-b43.13 as an immunotherapeutic treatment of epithelial ovarian cancer: experience as single agent post first-line therapy and in combination with chemotherapy in recurrent disease
    Volume: 38 Page(s): S137 - S137
    11/01/2002 Authors: Schultes BC; Nicodemus CF; Berek JS; Ehlen TA; Gordon AN; Whiteside TL
  • A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK.
    Ann Oncol Volume: 13 Page(s): 1590 - 1597
    10/01/2002 Authors: Smith DH; Adams JR; Johnston SRD; Gordon A; Drummond MF; Bennett CL
  • Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gynecol Oncol Volume: 85 Page(s): 129 - 135
    04/01/2002 Authors: Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
  • Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.
    Nat Med Volume: 7 Page(s): 1339 - 1346
    12/01/2001 Authors: Zou W; Machelon V; Coulomb-L'Hermin A; Borvak J; Nome F; Isaeva T; Wei S; Krzysiek R; Durand-Gasselin I; Gordon A
  • Clinical activity of Irofulven in pretreated advanced ovarian cancer (AOC) patients.
    CLINICAL CANCER RESEARCH Volume: 7 Page(s): 3697S - 3697S
    11/01/2001 Authors: Reed E; Sarosy GA; Gordon AN; Weems G; Herdrich L
  • Monoclonal antibody (Oregovomab) targeting of CA125 in patients (Pts) with advanced epithelial ovarian cancer (EOC) and elevated CA125 after response to initial therapy.
    CLINICAL CANCER RESEARCH Volume: 7 Page(s): 3756S - 3756S
    11/01/2001 Authors: Bookman M; Rettenmaier M; Gordon A; Tuccillo D; Fingert H
  • Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
    J Clin Oncol Volume: 19 Page(s): 3312 - 3322
    07/15/2001 Authors: Gordon AN; Fleagle JT; Guthrie D; Parkin DE; Gore ME; Lacave AJ
  • Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
    J Clin Oncol Volume: 19 Page(s): 1893 - 1900
    04/01/2001 Authors: Gore M; ten Bokkel Huinink W; Carmichael J; Gordon A; Davidson N; Coleman R; Spaczynski M; Hron JF; Bolis G; Malmstrm H
  • Conflicting phase II efficacy data for Doxil.
    J Clin Oncol Volume: 19 Page(s): 596 - 597
    01/15/2001 Authors: Frykman G; Williams G; Pazdur R
  • Conflicting phase II efficacy data for Doxil - Reply
    JOURNAL OF CLINICAL ONCOLOGY Volume: 19 Page(s): 596 - 597
    01/15/2001 Authors: Gordon AN
  • Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
    J Clin Oncol Volume: 18 Page(s): 3093 - 3100
    09/01/2000 Authors: Gordon AN; Granai CO; Rose PG; Hainsworth J; Lopez A; Weissman C; Rosales R; Sharpington T
  • Tumor ascites macrophages (M phi s) in ovarian carcinoma are dendritic cell precursors.
    Volume: 14 Page(s): A944 - A944
    04/20/2000 Authors: Borvak J; Zou W; Marches F; Isaeva T; Stringer CA; Matthews C; Gordon A; Curiel T
  • A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel.
    Am J Clin Oncol Volume: 22 Page(s): 601 - 605
    12/01/1999 Authors: Gordon AN; Hancock KC; Matthews CM; Stringer CA; Boston J; Nemunaitis J
  • Phase I study of topotecan (T) with carboplatin (C) alternating with paclitaxel (P) via 3 hour infusion with carboplatin (C) in treatment of newly diagnosed ovarian cancer (OC)
    Volume: 35 Page(s): S237 - S237
    09/01/1999 Authors: Gordon AN; Doherty M; Hancock KC; Messing M; Matthews CM; Teneriello M; Patton T; Stringer CA
  • Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    J Clin Oncol Volume: 16 Page(s): 3345 - 3352
    10/01/1998 Authors: Bookman MA; Malmstrm H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
  • Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
    J Clin Oncol Volume: 15 Page(s): 2183 - 2193
    06/01/1997 Authors: ten Bokkel Huinink W; Gore M; Carmichael J; Gordon A; Malfetano J; Hudson I; Broom C; Scarabelli C; Davidson N; Spanczynski M
  • Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
    J Clin Oncol Volume: 15 Page(s): 1965 - 1973
    05/01/1997 Authors: Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
  • Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    Semin Oncol Volume: 24 Page(s): S5-19-S5-25
    02/01/1997 Authors: ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
  • Current concepts in the treatment of invasive vulvar carcinoma.
    Clin Obstet Gynecol Volume: 34 Page(s): 587 - 598
    09/01/1991 Authors: Gordon AN
  • Depth of myometrial invasion in endometrial cancer: preoperative assessment by transvaginal ultrasonography.
    Gynecol Oncol Volume: 39 Page(s): 321 - 327
    12/01/1990 Authors: Gordon AN; Fleischer AC; Reed GW
  • Transvaginal sonography of postmenopausal ovaries with pathologic correlation.
    J Ultrasound Med Volume: 9 Page(s): 637 - 644
    11/01/1990 Authors: Fleischer AC; McKee MS; Gordon AN; Page DL; Kepple DM; Worrell JA; Jones HW; Burnett LS; James AE
  • Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis.
    Gynecol Oncol Volume: 38 Page(s): 305 - 308
    09/01/1990 Authors: Stringer CA; Gershenson DM; Burke TW; Edwards CL; Gordon AN; Wharton JT
  • Transvaginal scanning of the endometrium.
    J Clin Ultrasound Volume: 18 Page(s): 337 - 349
    05/01/1990 Authors: Fleischer AC; Gordon AN; Entman SS; Kepple DM
  • Survival after malignant pericardial effusion and cardiac tamponade in advanced ovarian cancer.
    South Med J Volume: 83 Page(s): 241 - 242
    02/01/1990 Authors: Levitan Z; Kaplan AL; Gordon AN
  • Transvaginal sonography (TVS) of the endometrium: current and potential clinical applications.
    Crit Rev Diagn Imaging Volume: 30 Page(s): 85 - 110
    01/01/1990 Authors: Fleischer AC; Gordon AN; Entman SS; Kepple DM
  • Sarcoma botryoides of the cervix: excision followed by adjuvant chemotherapy for preservation of reproductive function.
    Gynecol Oncol Volume: 36 Page(s): 119 - 124
    01/01/1990 Authors: Gordon AN; Montag TW
  • Human papillomavirus associated with adenocarcinoma and adenosquamous carcinoma of the cervix: analysis by in situ hybridization.
    Gynecol Oncol Volume: 35 Page(s): 345 - 348
    12/01/1989 Authors: Gordon AN; Bornstein J; Kaufman RH; Estrada RG; Adams E; Adler-Storthz K
  • Response of lower genital tract flora to external pelvic irradiation.
    Gynecol Oncol Volume: 35 Page(s): 233 - 235
    11/01/1989 Authors: Gordon AN; Martens M; LaPread Y; Faro S
  • Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography (US) and magnetic resonance imaging (MRI).
    Gynecol Oncol Volume: 34 Page(s): 175 - 179
    08/01/1989 Authors: Gordon AN; Fleischer AC; Dudley BS; Drolshagan LF; Kalemeris GC; Partain CL; Jones HW; Burnett LS
  • High-risk metastatic gestational trophoblastic disease: further stratification into two clinical entities.
    Gynecol Oncol Volume: 34 Page(s): 54 - 56
    07/01/1989 Authors: Gordon AN; Gershenson DM; Copeland LJ; Stringer CA; Morris M; Wharton JT
  • Squamous carcinoma of the cervix complicating pregnancy: recurrence in episiotomy after vaginal delivery.
    Obstet Gynecol Volume: 73 Page(s): 850 - 852
    05/01/1989 Authors: Gordon AN; Jensen R; Jones HW
  • Primary malignant melanoma of the vagina: report of four cases and review of the literature.
    Gynecol Oncol Volume: 33 Page(s): 85 - 90
    04/01/1989 Authors: Levitan Z; Gordon AN; Kaplan AL; Kaufman RH
  • Transabdominal and transvaginal sonography of pelvic masses.
    Ultrasound Med Biol Volume: 15 Page(s): 529 - 533
    01/01/1989 Authors: Fleischer AC; Gordon AN; Entman SS
  • Early discharge after vaginal hysterectomy.
    Obstet Gynecol Volume: 72 Page(s): 681 - 682
    10/01/1988 Authors: Gordon AN
  • Conservative management of abdominal gunshot wound in a pregnant woman.
    Am J Perinatol Volume: 5 Page(s): 232 - 233
    07/01/1988 Authors: Kirshon B; Young R; Gordon AN
  • Small-cell carcinoma of the ovary: an aggressive epithelial cancer occurring in young patients.
    Gynecol Oncol Volume: 29 Page(s): 365 - 369
    03/01/1988 Authors: Pruett KM; Gordon AN; Estrada R; Lynch GR
  • Sigmoidovaginal fistula secondary to diverticular disease. A report of three cases.
    J Reprod Med Volume: 33 Page(s): 313 - 316
    03/01/1988 Authors: Reeves KO; Young RL; Gordon AN; Thomas SJ; Redwine WA; Edwards GR
  • Multi-agent chemotherapy in combination with fractioned radiation therapy for advanced carcinoma of the cervix: acute toxicity.
    Eur J Gynaecol Oncol Volume: 9 Page(s): 351 - 354
    01/01/1988 Authors: Gordon AN; Lynch GR
  • Malignant fibrous histiocytoma of the broad ligament: a case report and literature review.
    Gynecol Oncol Volume: 28 Page(s): 225 - 229
    10/01/1987 Authors: Dieste MC; Lynch GR; Gordon A; Estrada R; Lane M
  • Detection of human papillomavirus DNA in advanced epithelial ovarian carcinoma.
    Gynecol Oncol Volume: 27 Page(s): 340 - 349
    07/01/1987 Authors: Kaufman RH; Bornstein J; Gordon AN; Adam E; Kaplan AL; Adler-Storthz K
  • HUMAN PAPILLOMA-VIRUS TYPE-VI ASSOCIATED WITH ADVANCED EPITHELIAL OVARIAN-CARCINOMA
    Volume: 26 Page(s): 410 - 410
    03/01/1987 Authors: KAUFMAN R; GORDON A; BORNSTEIN J; ADAM E; KAPLAN A; ADLERSTORTHZ K
  • Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease.
    Cancer Volume: 58 Page(s): 1407 - 1410
    10/01/1986 Authors: Gordon AN; Kavanagh JJ; Gershenson DM; Saul PB; Copeland LJ; Stringer CA
  • COMBINATION CHEMOTHERAPY WITH CISPLATINUM, VINBLASTINE, AND BLEOMYCIN (PVB) IN RESIDENT GESTATIONAL TROPHOBLASTIC DISEASE
    Volume: 23 Page(s): 245 - 245
    02/01/1986 Authors: GORDON AN; KAVANAGH JJ; GERSHENSON DM; SAUL PB; STRINGER CA
  • Value of umbilical blood acid-base studies in fetal assessment.
    J Reprod Med Volume: 30 Page(s): 329 - 336
    04/01/1985 Authors: Gordon A; Johnson JW
  • High-risk metastatic gestational trophoblastic disease.
    Obstet Gynecol Volume: 65 Page(s): 550 - 556
    04/01/1985 Authors: Gordon AN; Gershenson DM; Copeland LJ; Saul PB; Kavanagh JJ; Edwards CL
  • Successful treatment of leptomeningeal relapse of epithelial ovarian cancer.
    Gynecol Oncol Volume: 18 Page(s): 119 - 124
    05/01/1984 Authors: Gordon AN; Kavanagh JJ; Wharton JT; Rutledge FN; Obbens EA; Bodey GP
  • Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry.
    Obstet Gynecol Volume: 58 Page(s): 497 - 504
    10/01/1981 Authors: Gordon A; Lipton D; Woodruff JD
  • Benign cystic teratomas in postmenopausal women.
    Am J Obstet Gynecol Volume: 138 Page(s): 1120 - 1123
    12/15/1980 Authors: Gordon A; Rosenshein N; Parmley T; Bhagavan B
  • Fetal death without preceding fetal movement.
    N Engl J Med Volume: 303 Page(s): 1419 - 1420
    12/11/1980 Authors: Payne PA; Gordon AN; Johnson TR
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements